Rockefeller Capital Management
SMMT icon

Rockefeller Capital Management’s Summit Therapeutics SMMT Stock Holding History

Rockefeller Capital Management’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$862 Buy
51
+41
+410% +$613 ﹤0.01% 4665
2026
Q2 		$146 Sell
10
-27
-73% -$479 ﹤0.01% 4673
2026
Q1 		$702 Buy
+37
New +$598 ﹤0.01% 4534
2025
Q4 		– Sell
-33
Closed -$682 – 4827
2025
Q3 		$682 Buy
+33
New +$800 ﹤0.01% 4230

Other funds holding SMMT

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
Candriam SCA
Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.96T AUM 27.49% 1-Year Est. Return

Rockefeller Capital Management's SMMT Position: Q3 2026 in Review

Rockefeller Capital Management increased its Summit Therapeutics (SMMT) stake by 410% in Q3 2026, buying an estimated $613 and bringing the position to 51 shares worth $862. The position accounts for ﹤0.01% of the portfolio, ranked #4665.

Rockefeller Capital Management first reported a position in SMMT in Q3 2025 and has held it in 4 quarters since. 211 funds tracked by Wall St. Rank hold SMMT as of Q3 2026.

  • Rockefeller Capital Management held 51 shares of Summit Therapeutics worth $862 as of Q3 2026.
  • Rockefeller Capital Management bought 41 Summit Therapeutics shares in Q3 2026, an estimated $613.
  • Summit Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #4665 holding.
  • Rockefeller Capital Management first reported a position in Summit Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 211 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2026.

Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.